Ablacon Announces Release of New and Improved Ablamap Technology Under Existing CE Mark

MENLO PARK, Calif., Sept. 10, 2019 /PRNewswire/ — Ablacon, Inc. (www.ablacon.com), an Ajax Health-funded company, announced today the release of an updated version of its Ablamap technology under the company’s existing CE Mark.  The new update includes an enhanced physician experience and user interface, along with significantly faster processing times leading to improved procedural efficiency.  It will be rolled out to all current centers and will be used in the upcoming FLOW-AF clinical study, which will study the technology in patients with persistent atrial fibrillation (AFib). 

View Full Press Release